BridgeBio Pharma Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.25%.
Did BBIO Beat Earnings? Q3 2025 Results
BridgeBio Pharma delivered a mixed Q3 2025 report, posting revenue that cleared Wall Street's bar while earnings fell short, as the company's explosive Attruby commercial launch collided with the heavy costs of building a multi-product genetic medicine franchise. Revenue surged to $120.70 million, a staggering 4,318% jump year-over-year and well above the $105.67 million consensus, driven almost entirely by $108.11 million in U.S. net product sales of Attruby for ATTR-CM, a drug that generated zero revenue in the year-ago period. On the bottom line, however, BridgeBio missed, reporting a loss of $0.95 per share against the $0.78 consensus estimate, a 22.31% shortfall, as SG&A expenses climbed $68.80 million to fund the launch and noncash interest charges on a new royalty monetization deal added $36.41 million in costs. The pipeline simultaneously delivered registrational wins, with BBP-418 and encaleret both meeting Phase 3 primary endpoints; BridgeBio plans NDA filings for both programs in the first half of 2026, a pipeline cadence that <a href="https://247wallst.com/investing/2025/10/27/biomarin-up-after-q3-earnings-heres-everything-you-need-to-know/">echoes momentum seen across rare disease peers</a> this earnings season.
- Strong Attruby commercial launch with 5,259 unique patient prescriptions by 1,355 unique prescribers since FDA approval in November 2024
- Accelerating growth in treatment-naïve patient segment
- Attruby clinical differentiation with JACC publication showing cardiovascular outcome benefits within first month of treatment
- 49% hazard reduction in cardiovascular mortality or recurrent cardiovascular-related hospitalizations at Month 30 versus placebo
- Royalty revenue from BEYONTTRA sales in EU and Japan
“Attruby's strong commercial performance continues to validate our model, delivering a potential best-in-class medicine to patients who were historically overlooked and building meaningful momentum across all market segments. We are now seeing that same success echoed in our pipeline with home-run data in both ADH1 and LGMD2I/R9, and we continue to advance one of the broadest and fastest-moving portfolios in genetic medicine.”
BridgeBio Pharma CEO, on the earnings call
Forward Guidance & Outlook
BridgeBio intends to file NDAs with the FDA for both BBP-418 (LGMD2I/R9) and encaleret (ADH1) in the first half of 2026, and plans to submit a Marketing Authorization Application to the EMA for encaleret. Topline results from PROPEL 3 for infigratinib in achondroplasia are expected in early 2026. The company plans to initiate Phase 3 studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, begin clinical trials of BBP-418 in pediatric LGMD2I/R9 and in LGMD2M/2U, and expects Phase 2 data from ACCEL 2/3 in hypochondroplasia in the second half of 2026. The company stated it is well capitalized with $645.9 million in cash, cash equivalents and marketable securities to commercialize Attruby and advance its late-stage pipeline.
BBIO YoY Financials
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.